Cagrilintide

A long-acting amylin analog studied (including in combination with GLP-1 agonists) for appetite regulation. Status: Investigational — not FDA-approved as a standalone product.

Act as a long-acting analog of the hormone amylin, which is naturally released from the pancreas together with insulin after meals.

Amylin helps regulate:

• Satiety (how full you feel)

• Gastric emptying (how fast food leaves the stomach)

• Post-meal blood sugar responses

Cagrilintide is engineered to mimic and prolong amylin’s effects, with the goal of:

• Increasing fullness

• Reducing food intake and cravings

• Supporting sustained weight loss

Educational note: Cagrilintide is not FDA-approved and remains in clinical trials.

Cagrilintide targets amylin receptors in the brain and gastrointestinal system. These receptors are formed by a calcitonin receptor plus RAMP proteins, which together create the “amylin receptor” complex.

Key proposed actions:

• In the brain (satiety centers):

  • Increases the feeling of fullness after eating

  • Reduces hedonic eating (eating for reward, not hunger)

• In the gut:

  • Slows gastric emptying, so food stays longer in the stomach

  • Helps flatten post-meal blood sugar spikes

• On metabolism:

  • May modestly increase energy expenditure

  • Reduces overall caloric intake over time

Think of cagrilintide as an amplified satiety hormone: it doesn’t burn fat directly, but it makes it much easier for the body to maintain a consistent calorie deficit, which leads to weight loss when combined with appropriate nutrition.

Cagrilintide has been studied as monotherapy (by itself) in people with overweight and obesity.

• Phase 2 trial (published 2021, once-weekly injection):

  • In adults with overweight or obesity, cagrilintide produced significant weight loss versus placebo and was generally well tolerated.

• Phase 3 REDEFINE-1 trial (late-stage, 68 weeks):

  • Average weight loss: about 11.8% of body weight with cagrilintide vs 2.3% with placebo over 68 weeks.

  • Roughly 1 in 3 participants on cagrilintide achieved ≥15% weight loss, compared with a small minority on placebo.

Common themes across trials:

• Weight loss is progressive and sustained over many months.

• Most participants lose a meaningful amount of body weight when they stay on therapy and adhere to the program.

• Gastrointestinal side effects (nausea, vomiting, diarrhea/constipation) are common but usually mild to moderate and transient.

Cagrilintide is also being developed in a fixed-dose combination with semaglutide (a GLP-1 agonist) called CagriSema.

• Mechanistic idea:

  • Semaglutide (GLP-1): reduces appetite, slows gastric emptying, improves blood sugar and insulin response.

  • Cagrilintide (amylin analog): enhances satiety, further delays gastric emptying, may increase energy expenditure.

• Phase 3 REDEFINE trials (68 weeks):

  • In adults with obesity without diabetes, CagriSema produced up to ≈20–22% average weight loss, clearly more than semaglutide alone, cagrilintide alone, or placebo.

  • In adults with type 2 diabetes, CagriSema also led to substantial weight loss (~15–16%) and improved glycemic control versus comparators.

These data are driving ongoing development and planned regulatory submissions for the combination therapy.

Across trials, the most common side effects of cagrilintide (alone or in CagriSema) are similar to other incretin-based and gut hormone–based obesity drugs:

• Common (usually mild–moderate):

  • Nausea

  • Vomiting

  • Diarrhea or constipation

  • Abdominal discomfort or bloating

• Less common but important to watch:

  • Possible gallbladder-related issues (like many weight-loss injectables)

  • Potential effects on heart rate, blood pressure, or pancreatitis risk are being monitored

In phase 2 and phase 3 studies:

• Cagrilintide and CagriSema were generally reported as well tolerated, with GI side effects that were often dose-dependent and transient, especially when doses were titrated gradually.

Long-term, real-world safety data are still limited, and ongoing trials are designed to better characterize cardiovascular and metabolic outcomes.

Cagrilintide sits at the next frontier of obesity pharmacology:

• It targets amylin, a hormone historically under-used in obesity treatment, offering a different mechanism than GLP-1 alone.

• Phase 3 data show double-digit average weight loss with monotherapy and 20%+ loss when combined with semaglutide in CagriSema.

• Trials also suggest improvements in blood pressure, inflammatory markers, and global cardiometabolic risk, especially with CagriSema.

Media and professional coverage position cagrilintide and CagriSema as part of a “post-Ozempic” generation of drugs that could offer deeper weight loss and broader health benefits, if long-term safety and regulatory hurdles are met.

• This page is for educational purposes only.

• Cagrilintide and CagriSema are investigational and not FDA-approved at this time.

• We do not prescribe, supply, or include Cagrilintide or CagriSema in any of our weight-management programs.

• We follow evidence-based, FDA-approved options and track emerging therapies (like Cagrilintide) so we can explain them clearly when patients see them in the news or online.

The information on this page does not constitute medical advice or an endorsement of any unapproved medication. Do not start, stop, or obtain any injectable weight-loss drug without consulting a licensed healthcare professional. Any use of Cagrilintide outside a regulated clinical trial involves unapproved products with uncertain safety, dosing, and quality.